Update on HLA-B*15:02 allele associated with adverse drug reactions

被引：0
作者：
Zhu, Xueting [1 ]
Luo, Guanghua [1 ]
Zheng, Lu [1 ]
机构：
[1] Soochow Univ, Affiliated Hosp 3, Clin Med Res Ctr, Changzhou, Peoples R China
来源：
PHARMACOGENOMICS | 2024年 / 25卷 / 02期
关键词：
adverse drug reactions; antiepileptic drug; genetic marker; HLA-B*15:02; review; STEVENS-JOHNSON-SYNDROME; TOXIC EPIDERMAL NECROLYSIS; POLYMERASE-CHAIN-REACTION; HLA CLASS-I; INDUCED MACULOPAPULAR EXANTHEMA; GENETIC-MARKERS; RISK-FACTOR; B LOCUS; CARBAMAZEPINE; HAN;
D O I：
10.2217/pgs-2023-0173
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
HLA alleles, part of the major histocompatibility complex, are strongly associated with adverse drug reactions (ADRs). This review focuses on HLA-B*15:02 and explores its association with ADRs in various ethnic populations and with different drugs, aiming to provide insights into the safe clinical use of drugs and minimize the occurrence of ADRs. Furthermore, the review explores the potential mechanisms by which HLA-B*15:02 may be associated with ADRs, aiming to gain new insights into drug modification and identification of haptens. In addition, it analyzes the frequency of the HLA-B*15:02, genotyping methods, cost-effectiveness and treatment measures for adverse reactions, thereby providing a theoretical basis for formulating clinical treatment plans.
引用
收藏
页码：97 / 111
页数：15
相关论文
共 50 条
  • [1] Accurate identification of HLA-B*15:02 allele by two-dimensional polymerase chain reaction
    Zhu, Xueting
    Yu, Yang
    Zhang, Jun
    Zhan, Yuxia
    Luo, Guanghua
    Zheng, Lu
    CLINICA CHIMICA ACTA, 2024, 552
  • [2] HLA-B*15:11 status and carbamazepine-induced severe cutaneous adverse drug reactions in HLA-B*15:02 negative Chinese
    Wong, Christina S. M.
    Yap, Desmond Y. H.
    Ip, Patrick
    Wong, Wilfred H. S.
    Chua, Gilbert T.
    Yeung, Chi-Keung
    Chan, Henry H. L.
    Kwok, Janette S. Y.
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2022, 61 (02) : 184 - 190
  • [3] Association of HLA-B*15:13 and HLA-B*15:02 with phenytoin-induced severe cutaneous adverse reactions in a Malay population
    Chang, C-C
    Ng, C-C
    Too, C-L
    Choon, S-E
    Lees, C-K
    Chung, W-H
    Hussein, S. H.
    Lim, K-S
    Murad, S.
    PHARMACOGENOMICS JOURNAL, 2017, 17 (02) : 170 - 173
  • [4] Association between HLA-B*15:02 and carbamazepine induced severe cutaneous adverse drug reactions in Myanmar
    Khor, Amy Hui-Ping
    Aye, Seinn Mya Mya
    Lim, Kheng-Seang
    Aung, Yan Lynn
    Aye, Yin Minn
    Ohnmar
    Thit, Win Min
    Tan, Chong-Tin
    Ng, Ching-Ching
    NEUROLOGY ASIA, 2017, 22 (03) : 283 - 285
  • [5] Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand
    Rattanavipapong, Waranya
    Koopitakkajorn, Tanunya
    Praditsitthikorn, Naiyana
    Mahasirimongkol, Surakameth
    Teerawattananon, Yot
    EPILEPSIA, 2013, 54 (09) : 1628 - 1638
  • [6] External quality assessment for laboratory testing of HLA-B*15:02 allele in relation to carbamazepine therapy
    Lin, Guigao
    Zhang, Kuo
    Han, Yanxi
    Xie, Jiehong
    Li, Jinming
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2018, 32 (02)
  • [7] Effects of a HLA-B*15:02 screening policy on antiepileptic drug use and severe skin reactions
    Chen, Zhibin
    Liew, Danny
    Kwan, Patrick
    NEUROLOGY, 2014, 83 (22) : 2077 - 2084
  • [8] HLA-B*5701 and HLA-B*5801 in an Indian patient with anti-epileptics induced cutaneous adverse drug reactions
    Manoharan, Aarthi
    Kumar, Ajay Sam
    Sreedevi, Ambujam
    Sathishkannan, Aruna Devi
    Gaddam, Bhargav Kiran
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 75 (04) : 599 - 601
  • [9] The HLA-B*15:02 polymorphism and Tegretol®-induced serious cutaneous reactions in epilepsy: An updated systematic review and meta-analysis
    Chouchi, M.
    Kaabachi, W.
    Tizaoui, K.
    Daghfous, R.
    Aidli, S. E.
    Hila, L.
    REVUE NEUROLOGIQUE, 2018, 174 (05) : 278 - 291
  • [10] Usage Pattern of Carbamazepine and Associated Severe Cutaneous Adverse Reactions in Singapore Following Implementation of HLA-B*15:02 Genotyping as Standard-of-Care
    Sung, Cynthia
    Tan, Liesbet
    Limenta, Michael
    Ganesan, Ganga
    Toh, Dorothy
    Chan, Cheng Leng
    FRONTIERS IN PHARMACOLOGY, 2020, 11
12345